Cardiovascular risk associated with white-coat hypertension: Pro side of the argument

Hypertension

Volumn 70, Issue 4, 2017, Pages 668-675

  Mancia, Giuseppe ^a   Bombelli, Michele ^a   Cuspidi, Cesare ^a,b   Facchetti, Rita ^c   Grassi, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; ASYMPTOMATIC DISEASE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; DIABETES MELLITUS; HUMAN; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; WHITE COAT HYPERTENSION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; COMPLICATION; RISK FACTOR;

BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; WHITE COAT HYPERTENSION;

EID: 85041276194     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.08903     Document Type: Article

References (60)

1. Pickering TG, Harshfeld GA, Devereux RB, Laragh JH. What is the role of ambulatory blood pressure monitoring in the management of hypertensive patients? Hypertension. 1985;7:171-177.
2. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc.
3. Weber MA, Neutel JM, Smith DH, Graettinger WF. Diagnosis of mild hypertension by ambulatory blood pressure monitoring. Circulation. 1994;90:2291-2298.
4. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in offce, home, and ambulatory blood pressure. Hypertension. 2006;47:846-853. doi: 10.1161/01.HYP.0000215363.69793.bb.
5. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33:1729-1741. doi: 10.1097/HJH.0000000000000701.
6. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Blood pressure monitoring. Task force V: white-coat hypertension. Blood Press Monit. 1999;4:333-341.
7. Kotsis V, Stabouli S, Toumanidis S, Papamichael C, Lekakis J, Germanidis G, Hatzitolios A, Rizos Z, Sion M, Zakopoulos N. Target organ damage in "white coat hypertension" and "masked hypertension". Am J Hypertens. 2008;21:393-399. doi: 10.1038/ajh.2008.15.
8. Høegholm A, Bang LE, Kristensen KS, Nielsen JW, Holm J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension. 1994;24:101-105.
9. Kario K, Shimada K, Schwartz JE, Matsuo T, Hoshide S, Pickering TG. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol. 2001;38:238-245.
10. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, Valagussa F, Bombelli M, Giannattasio C, Zanchetti A, Mancia G. Alterations of cardiac structure in patients with isolated offce, ambulatory, or home hyper tension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001;104:1385-1392.
11. Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G, Mancia G. White-coat hypertension, as defned by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. J Hypertens. 2015;33:24-32. doi: 10.1097/HJH.0000000000000416.
12. Cuspidi C, Sala C, Tadic M, Rescaldani M, Grassi G, Mancia G. Is white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis. Blood Press Monit. 2015;20:57-63. doi: 10.1097/MBP.0000000000000094.
13. Grassi G, Seravalle G, Trevano FQ, Dell'oro R, Bolla G, Cuspidi C, Arenare F, Mancia G. Neurogenic abnormalities in masked hypertension. Hypertension. 2007;50:537-542. doi: 10.1161/HYPERTENSIONAHA. 107.092528.
14. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114:1804-1814. doi: 10.1161/CIRCRESAHA.114.302524.
15. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-565. doi: 10.1161/01. CIR.0000081775.72651.B6.
16. Bevan RD. Trophic effects of peripheral adrenergic nerves on vascular structure. Hypertension. 1984;6(6 pt 2):III19-III26.
17. Mancia G. Short-and long-term blood pressure variability: present and future. Hypertension. 2012;60:512-517. doi: 10.1161/HYPERTENSIONAHA.112.194340.
18. Mancia G, Facchetti R, Parati G, Zanchetti A. Effect of long-term anti-hypertensive treatment on white-coat hypertension. Hypertension. 2014;64:1388-1398. doi: 10.1161/HYPERTENSIONAHA.114.04278.
19. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, Grassi G, Sega R. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-232. doi: 10.1161/HYPERTENSIONAHA.109.129882.
20. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Grassi G, Sega R. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens. 2009;27:1672-1678. doi: 10.1097/HJH.0b013e32832be5f9.
21. Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management-is nice always good? J Hypertens. 2012;30:660-668. doi: 10.1097/HJH.0b013e328351b4e4.
22. Ugajin T, Hozawa A, Ohkubo T, Asayama K, Kikuya M, Obara T, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Tsuji I, Imai Y. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med. 2005;165:1541-1546. doi: 10.1001/archinte.165.13.1541.
23. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normoten-sion: a meta-analysis. J Hypertens. 2007;25:2193-2198. doi: 10.1097/HJH.0b013e3282ef6185.
24. Pierdomenico SD, Lapenna D, Di Mascio R, Cuccurullo F. Short-and long-term risk of cardiovascular events in white-coat hypertension. J Hum Hypertens. 2008;22:408-414. doi: 10.1038/jhh.2008.6.
25. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens. 2011;24:52-58. doi: 10.1038/ajh.2010.203.
26. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T, Kario K. Short-and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-208. doi: 10.1161/01.HYP.0000151623.49780.89.
27. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593-599. doi: 10.1097/HJH.0000000000000832.
28. Huang Y, Huang W, Mai W, Cai X, An D, Liu Z, Huang H, Zeng J, Hu Y, Xu D. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677-688. doi: 10.1097/HJH.0000000000001226.
29. Muntner P, Booth JN 3rd, Shimbo D, Schwartz JE. Is white-coat hypertension associated with increased cardiovascular and mortality risk? J Hypertens. 2016;34:1655-1658. doi: 10.1097/HJH.0000000000000983.
30. Sega R, Cesana G, Milesi C, Grassi G, Zanchetti A, Mancia G. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension. 1997;30(1 pt 1):1-6.
31. National Institute for Health and Care Excellence (NICE). Hypertension in Adults: Diagnosis and Management. Clinical Guideline 127. Published date: August 2011. Last updated: November 2016. https://www.nice.org. uk/guidance/cg127.
32. Franklin SS, Thijs L, Hansen TW, et al; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Signifcance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012;59:564-571. doi: 10.1161/HYPERTENSIONAHA.111.180653.
33. Franklin SS, Thijs L, Asayama K, et al; IDACO Investigators. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol. 2016;68:2033-2043. doi: 10.1016/j.jacc.2016.08.035.
34. Ben-Dov IZ, Kark JD, Mekler J, Shaked E, Bursztyn M. The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study. J Hypertens. 2008;26:699-705. doi: 10.1097/HJH.0b013e3282f4b3bf.
35. Eguchi K, Hoshide S, Ishikawa J, Ishikawa S, Pickering TG, Gerin W, Ogedegbe G, Schwartz JE, Shimada K, Kario K. Cardiovascular prognosis of sustained and white-coat hypertension in patients with type 2 diabetes mellitus. Blood Press Monit. 2008;13:15-20. doi: 10.1097/MBP.0b013e3282f13f4a.
36. Mancia G, Grassi G. The heterogeneous nature of white-coat hypertension. J Am Coll Cardiol. 2016;68:2044-2046. doi: 10.1016/j.jacc.2016.08.043.
37. Mancia G, Grassi G Aggressive blood pressure lowering is dangerous. The J-curve. Pro-side of the argument. Hypertension 2013, 63:29-36.
38. Chowdhury R, Khan H, Heydon E, Shrouf A, Fahimi S, Moore C, Stricker B, Mendis S, Hofman A, Mant J, Franco OH. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940-2948. doi: 10.1093/eurheartj/eht295.
39. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26:819-824. doi: 10.1097/HJH.0b013e3282f4edd7.
40. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-546.
41. Dolan E, Stanton AV, Thom S, Caulfeld M, Atkins N, McInnes G, Collier D, Dicker P, O'Brien E; ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients-an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2009;27:876-885. doi: 10.1097/HJH.0b013e328322cd62.
42. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with offce blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-1783. doi: 10.1161/01.CIR.0000160923.04524.5B.
43. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res. 2015;116:1034-1045. doi: 10.1161/CIRCRESAHA.116.303755.
44. Boggia J, Li Y, Thijs L, et al; International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370:1219-1229. doi: 10.1016/S0140-6736(07)61538-4.
45. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Predictors of all-cause mortality in clinical ambulatory monitoring: unique aspects of blood pressure during sleep. Hypertension. 2007;49:1235-1241. doi: 10.1161/HYPERTENSIONAHA.107.087262.
46. Myers MG. Statistical analysis as a cause of white-coat hypertension. J Hypertens. 2017;35:707-709. doi: 10.1097/HJH.0000000000001232.
47. Mancia G, Facchetti R, Grassi G, Bombelli M. Adverse prognostic value of persistent offce blood pressure elevation in white coat hypertension. Hypertension. 2015;66:437-444. doi: 10.1161/HYPERTENSIONAHA.115.05367.
48. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, Grassi G. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168-174. doi: 10.1161/HYPERTENSIONAHA.111.00690.
49. Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, Johnson E, Petrin J, Sekkarie MA, Kjeldsen SE. "White coat" versus "sus-tained" borderline hypertension in Tecumseh, Michigan. Hypertension. 1990;16:617-623.
50. Fagard RH, Staessen JA, Thijs L, et al. Response to antihyper-tensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation. 2000;102:1139-1144.
51. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-967. doi: 10.1016/S0140-6736(15)01225-8.
52. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels-overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2296-2304. doi: 10.1097/HJH.0000000000000379.
53. Five-year fndings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1982;247:633-638.
54. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed). 1985;291:97-104.
55. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898. doi: 10.1056/NEJMoa0801369.
56. Bulpitt CJ, Beckett N, Peters R, Staessen JA, Wang JG, Comsa M, Fagard RH, Dumitrascu D, Gergova V, Antikainen RL, Cheek E, Rajkumar C. Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project. Hypertension. 2013;61:89-94. doi: 10.1161/HYPERTENSIONAHA.112.191791.
57. Mancia G, Zanchetti A. White-coat hypertension: misnomers, miscon-ceptions and misunderstandings. What should we do next? J Hypertens. 1996;14:1049-1052.
58. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, Gregorini L, Zanchetti A. Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet. 1983;2:695-698.
59. Parati G, Omboni S, Staessen J, Thijs L, Fagard R, Ulian L, Mancia G. Limitations of the difference between clinic and daytime blood pressure as a surrogate measure of the 'white-coat' effect. Syst-Eur investigators. J Hypertens. 1998;16:23-29.
60. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension. 1998;31:1185-1189.